Published in final edited form as:

Bioorg Med Chem Lett. 2010 September 1; 20(17): 5179–5183. doi:10.1016/j.bmcl.2010.07.003.

Synthesis and Evaluation of Oryzalin Analogs against *Toxoplasma gondii*

Molla M. Endeshaw^a, Catherine Li^b, Jessica de Leon^b, Ni Yao^b, Kirk Latibeaudiere^a, Kokku Premalatha^a, Naomi Morrisette^b, and Karl A. Werbovetz^{a,*}

^aDivision of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210

^bDepartment of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA, 92697

Abstract

The synthesis and evaluation of twenty dinitroanilines and related compounds against the obligate intracellular parasite *Toxoplasma gondii* is reported. Using *in vitro* cultures of parasites in human fibroblasts, we determined that most of these compounds selectively disrupted *Toxoplasma* microtubules, and several displayed sub-micromolar potency against the parasite. The most potent compound was *N*¹,*N*¹-dipropyl-2,6-dinitro-4-(trifluoromethyl)-1,3-benzenediamine (**18b**), which displayed an IC₅₀ value of 36 nM against intracellular *T. gondii*. Based on these data and another recent report (Ma, C.; Tran, J.; Gu, F.; Ochoa, R.; Li, C.; Sept, D.; Werbovetz, K.; Morrisette, N. *Antimicrob. Agents Chemother.* 2010, 54, 1453), an antimitotic structure-activity relationship for dinitroanilines vs. *Toxoplasma* is presented.

Infection by the apicomplexan parasite *Toxoplasma gondii* can result in miscarriage, birth defects in infants, vision disturbances in immunocompetent hosts, and toxoplasmic encephalitis in the immunocompromised.¹ Acute toxoplasmosis in otherwise healthy individuals is typically treated with the antifolate combination of pyrimethamine and sulfadiazine together with folinic acid.¹ Pyrimethamine has potential side effects, including bone marrow suppression² and teratogenicity.^{3, 4} Resistance to pyrimethamine in malaria chemotherapy can occur through mutations in the dihydrofolate reductase target protein,⁵ although no evidence for clinical resistance to pyrimethamine in *Toxoplasma* exists to date.⁶ Sulfadiazine use is also complicated by the occurrence of kidney stones,⁷ allergic reactions,⁸ and the development of resistance.⁶ Other alternatives to pyrimethamine-sulfadiazine treatment of toxoplasmosis include clindamycin, atovaquone, and spiramycin,¹ but these drugs each possess their own limitations.^{9–11} An ideal drug against human toxoplasmosis would kill the different stages of *T. gondii*, be well distributed in the main sites of infection, including the brain and eyes, and lack the potential for teratogenicity.

© 2010 Elsevier Ltd. All rights reserved.

*To whom correspondence should be addressed. Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210-1291. Phone: 614-292-5499. Fax: 614-292-2435. werbovetz.1@osu.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Tubulin, which assembles into microtubules, is an essential protein for formation of the mitotic spindle. It continues to be a prime target for established and investigational anticancer agents^{12, 13} and is also believed to be the molecular target of anthelmintic benzimidazoles.¹⁴ Dinitroanilines are tubulin-binding herbicides which display microtubule selective toxicity for many different classes of protozoan parasites, including *Leishmania*, *Trypanosoma*, *Plasmodium*, and *Toxoplasma*. We have previously characterized the sensitivity of *Toxoplasma* to dinitroanilines and have found that IC₅₀ values for commercially available dinitroanilines range from 45 nM to 6.7 μ M.^{15–17} *Toxoplasma* parasites only replicate inside of host cells, and extracellular parasites do not have dynamic microtubules. Intracellular *Toxoplasma* parasites are sensitive to disruption by dinitroanilines: dinitroaniline-treated parasites lack all microtubules and cannot carry out microtubule-dependent functions including mitosis and cytokinesis.^{15, 18, 19}

Following lysis of the original host cell, round, non-polar dinitroaniline-treated parasites are unable to invade new host cells and rapidly die. Thus, dinitroanilines could serve as excellent leads for the discovery of new drugs against toxoplasmosis since they disrupt protozoan parasite microtubules at nanomolar concentrations while showing little or no effect on host cell microtubules.^{16, 20–23} Computational methods have been used to identify a binding site for the dinitroanilines on parasite tubulin.^{16, 24} These studies predict that protofilament contacts in the microtubule lattice are disrupted when dinitroanilines selectively bind to protozoan α -tubulin beneath the H1-S2 loop. Analysis of vertebrate α -tubulin through computational methods indicates that oryzalin has non-specific, low affinity interactions with this protein and no consensus binding site, consistent with *in vivo* and *in vitro* observations that dinitroanilines do not bind to vertebrate tubulin or disrupt vertebrate microtubules.^{20, 25–28}

Previous work in our laboratories has shown that structural modification of the commercial dinitroaniline oryzalin leads to increased potency against kinetoplastid parasites.^{23, 29, 30} However, a detailed structure-activity study of dinitroanilines against *Toxoplasma* has not been reported. We were therefore motivated to synthesize analogs of oryzalin (**6i**) and other dinitroaniline herbicides such as trifluralin (**14a**) and dinitramine (**18a**) for testing against *Toxoplasma gondii*. In the present manuscript, we describe the synthesis and biological activity of such derivatives.

To synthesize several of the desired target compounds, unsymmetrical secondary amines were needed. The required secondary amine salts were synthesized using the method reported previously.^{29,31} Hence, the standard coupling of the acid chlorides **1a–d** with amines gave the respective amides **2a–e**, followed by reduction with borane-THF solution, treatment with methanol, protection with Boc, and deprotection using HCl in dioxane to afford the secondary amine salts **3a–e** in good yields (see Scheme 1).

Dinitroaniline sulfonamide target compounds were prepared as shown in Scheme 2. The desired amines reacted with the potassium salt of 4-chloro-3,5-dinitrobenzenesulfonate **4** in the presence of triethylamine to give *N*⁴,*N*⁴-disubstituted-3,5-dinitrobenzenesulfonates **5a–e**, **5f–h**,³¹ and **5i–j**^{30, 31} in good yields. These sulfonates contained traces of the secondary amine salts as determined from their ¹H NMR spectra, but these salts did not interfere with further reactions. Sulfonyl chlorides were synthesized from benzenesulfonates **5a–j** using PCl₅ in dichloromethane. After brief work up, the resulting sulfonyl chlorides were treated with a methanolic solution of NH₃ or the desired amines in dry THF to afford the target compounds **6a–h**, **6i–j**,²⁹ **6k–l**, and **6m–n**³⁰ in good to excellent yields. Mono-*N*⁴-alkylated and free *N*⁴-amino sulfonamides were isolated as bi-products, especially for bulky *N*⁴,*N*⁴-disubstituted analogs such as **6a–g**.

The synthesis of **12**, where the nitro moieties present in **6i** were replaced with nitrile groups, was accomplished according to Scheme 3. The sulfonyl chloride corresponding to sulfonate **7**³² was prepared in situ from **7** using $\text{PCl}_5/\text{POCl}_3$ in dry chlorobenzene; treatment of this sulfonyl chloride with methanolic NH_3 afforded **8**. An Ullmann reaction³³ between sulfonamide **8** and dipropylamine in the presence of potassium carbonate and catalytic copper gave **9**. Hydrolysis of this ester using aqueous NaOH in methanol afforded **10**. Treatment of dicarboxylate **10** with hexachloroacetone and PPh_3 in THF followed by the addition of NH_3 in 1,4-dioxane provided bis-amide **11**. Dehydration of **11** using PdCl_2 in aqueous acetonitrile³⁴ afforded the target compound **12** in excellent and reproducible yield.

Trifluralin (**14a**) and its regioisomer **14b**³⁵ were prepared according to Scheme 4. Heating **13a** and **13b** to reflux in dipropylamine gave target compounds **14a** and **14b**, respectively, in excellent yield.

Dinitramine (**18a**) and its analogs were synthesized as shown in Scheme 5. 2,4-Dichloro-3,5-dinitrobenzotrifluoride (**16**) was prepared by nitration of 2,4-dichlorobenzotrifluoride (**15**) using fuming nitric acid in the presence of fuming sulfuric acid.³⁶ Dinitrobenzotrifluoride **16** was treated with 2.2 equivalents of each of the desired secondary amines and heated in a sealed flask at 100 °C.^{36, 37} After a brief workup, the crude products **17a–c** were dissolved in 3 equivalents of ammonia in dioxane and heated once again in a sealed flask at 100 °C, which gave the target compounds **18a–c** in 60–80% yield for two steps. The use of excess amine and sealed flask conditions were critical for the success of the latter two reactions.

Structures for the proposed target compounds were confirmed with the aid of ^1H and ^{13}C NMR spectroscopy and mass spectrometry analysis, while the purity of the compounds was verified by elemental analysis. Synthetic procedures and spectral data for representative target compounds **6h**, **12**, and **18b** are provided in the supplementary information.

The growth inhibitory activity of compounds of interest against *T. gondii* *in vitro* was measured by a plaque assay,¹⁷ with the results shown in Table 1. The IC_{50} values for **6i**, **14a**, and **18a** are consistent with those obtained previously in this assay.¹⁷ *Toxoplasma* microtubules were examined by an *in vitro* immunofluorescence assay (Figure 1). Figure 1A–B shows the effect of a selective antimitotic compound (**18b**), while Figure 1D–E illustrates the effect of a nonselective agent (**6e**). Experimental methods for both the plaque assay and the immunofluorescence assay are available in the supplementary information.

Among the compounds lacking a *meta*-amino group (**6a–n**, **12**, **14a**, and **14b**), the dinitroaniline oryzalin (**6i**) was the most effective against *Toxoplasma* in this study, possessing an IC_{50} value of 0.25 μM . In other studies examining the efficacy of commercially available dinitroanilines, **6i** was one of the most efficacious compounds to inhibit *Toxoplasma* growth as assessed by plaque assays.¹⁷ The other potent analogs of oryzalin are compounds **6h**, **6a**, and **6j**, with IC_{50} values ranging from 0.35 μM to 1.1 μM . These results indicate that alkyl chains of 3 or 4 carbons in length at the aniline nitrogen of the dinitroanilines confer strong activity against intracellular *T. gondii*. Compound **6g**, which possesses one four-carbon group and one benzyl group at the aniline nitrogen atom, is 8.5-fold less active than dipropyl derivative **6i** and twofold less active than dibutyl congener **6j**. Interestingly, compounds with two large substitutions at the aniline nitrogen (**6c–f**) do not appear to be tubulin specific inhibitors in *Toxoplasma*. These compounds inhibit parasite invasion, replication and growth at 10–25 μM without shortening the microtubules in the organism (Figure 1D–E, treatment with 30 μM **6e** shown) and display host HFF cell toxicity at ~30 μM . We also used a tetrazolium dye assay (Figure 1C) to quantify viable host HFF cells after 17 hours of treatment with 30 μM of two of the non-specific compounds (**6c** and

6e) and with a parasite-specific compound (0.5 μ M **18b**). Compounds **6c** and **6e** cause host cell vacuolation and dramatically decrease the number of viable host cells. Although **6c** and **6e** inhibit parasite replication, parasite microtubules are not disrupted, suggesting that they have a distinct target. In contrast, the specific compound **18b** does not compromise host cell viability at a concentration that selectively disrupts parasite microtubules.

Substitutions on the sulfonamide nitrogen decrease activity compared to **6i**. Compounds with 4-hydroxyphenyl (**6l**), phenyl (**6m**), dimethyl (**6n**), or 2-hydroxyethyl (**6k**) substituents at the sulfonamide nitrogen are 10- to 100-fold less active than **6i**. Interestingly, replacement of the nitro groups with nitrile moieties (**12**) results in a 19-fold drop in potency compared to **6i**. This is in contrast to the structure-activity relationship observed in kinetoplastid parasites, where exchanging nitrile groups for the nitro moieties present in the potent antikinoplastid compound **6m** results in only a 1.5- to 2-fold loss of potency.³²

Trifluralin (**14a**) is 2.6-fold less potent than **6i**, indicating that the sulfonamide group conveys greater potency against *Toxoplasma* than the trifluoromethyl group. A 12-fold decrease in potency compared to **14a** is observed for **14b**, a compound where the nitro and trifluoromethyl groups of **14a** are interchanged. The addition of the *meta*-amino group (compounds **18a–c**), however, causes a dramatic increase in activity compared to **14a**. Ma *et al.* recently reported that the *meta*-amino group present in **18a** participates in two critical hydrogen bonds with the α -tubulin target, significantly increasing the activity of this compound compared to both **14a** and **6i**.¹⁷ Our present study confirms this result for **18a** and also shows that the dipropylamino group found in **18b** imparts twofold greater potency against *Toxoplasma* compared to the *N,N*-diethyl substitution present in **18a** and 14-fold greater potency against this parasite compared to the *N,N*-di-*n*-butyl substitution occurring in **18c**. The selective antimitotic action of **18b** is illustrated in Figure 1A–B. Figure 1A1 shows well-defined microtubules present in both host cells and in *Toxoplasma* in the absence of compound treatment. In the presence of 0.5 μ M **18b**, host cell microtubules remain intact, while the diffuse staining of parasite tubulin reveals microtubule disruption in the parasites (Figure 1B1). Figure 1B also indicates that parasites exposed to 0.5 μ M **18b** are unable to replicate.

The results shown here, together with the data presented in Ma *et al.*¹⁷ concerning the evaluation of commercial dinitroanilines against *T. gondii*, permits us to develop an antimitotic structure-activity relationship for dinitroanilines vs. *Toxoplasma*. Isopropalin, a compound identical in structure to **6i** and **14a** except that it contains an isopropyl group *para* to the alkylamino position, reinforces the notion that sulfonamide-containing compounds are slightly superior to congeners with other substitutions at this position. As with compounds **6h** and **6j**, inclusion of a branched chain four carbon alkyl group in ethalfluralin leads to better activity than with benfluralin, which possesses an *n*-butyl group at the anilino nitrogen. The *meta*-amino derivatives **18a** and **18b** are 3.6- to 6.9-fold more potent than **6i** against *Toxoplasma* in vitro, and studies with **18a–c** suggest that the optimal chain length of the substitution on the aniline nitrogen is three carbons. These structure-activity data are summarized in Figure 2. Future efforts to optimize the anti-*Toxoplasma* potency and drug like properties of the dinitroanilines will focus on *meta*-amino containing derivatives **18a** and **18b** as lead compounds.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was funded by NIH Grants AI061021 (to K.A.W.) and AI067981 (to N.S.M.).

References and Notes

- Montoya J, Liesenfeld O. *Lancet* 2004;363:1965. [PubMed: 15194258]
- Kongsaengdao S, Samintarapanya K, Oranratnachai K, Prapakarn W, Apichartpiyakul C. *J. Int. Assoc. Physicians AIDS Care* 2008;7:11.
- Tsuda S, Kosaka Y, Matsusaka N, Sasaki Y. *Mutat. Res* 1998;415:69. [PubMed: 9711263]
- Misawa J, Kanda S, Kokue E, Hayama T, Teramoto S, Aoyama H, Kaneda M, Iwasaki T. *Toxicol. Lett* 1982;10:51. [PubMed: 7080067]
- Picot S, Oliaro P, Monbrison F, Bienvenu A, Price R, Ringwald P. *Malaria J* 2009;8:89.
- Meneceur P, Bouldouyre M, Aubert D, Villena I, Menotti J, Sauvage V, Garin J, Derouin F. *Antimicrob. Agents Chemother* 2008;52:1269. [PubMed: 18212105]
- Daudon M, Jungers P. *Drugs* 2004;64:245. [PubMed: 14871169]
- Dibbern D, Montanaro A. 2008;100:91.
- Dial S, Kezouh A, Dascal A, Barkun A, Suissa S. *CMAJ* 2008;179:767. [PubMed: 18838451]
- Megged O, Shalit I, Yaniv I, Stein J, Fisher S, Levy I. *Pediatr. Transplantation* 2008;12:902.
- Montoya J, Remington J. *Clin. Infect. Dis* 2008;47:554. [PubMed: 18624630]
- Morris P, Fornier M. *Expert Rev. Anticancer Ther* 2009;9:175. [PubMed: 19192956]
- Kanthou C, Tozer G. *Int. J. Exp. Pathol* 2009;90:284. [PubMed: 19563611]
- Martin R. *Vet. J* 1997;154:11. [PubMed: 9265850]
- Stokkermans T, Schwartzman J, Keenan K, Morrisette N, Tilney L, Roos D. *Exp. Parasitol* 1996;84:355. [PubMed: 8948325]
- Morrisette N, Mitra A, Sept D, Sibley L. *Mol. Biol. Cell* 2004;15:1960. [PubMed: 14742718]
- Ma C, Tran J, Gu F, Ochoa R, Li C, Sept D, Werbovetz K, Morrisette N. *Antimicrob. Agents Chemother* 2010;54:1453. [PubMed: 20145086]
- Morrisette N, Sibley L. *J. Cell Sci* 2002;115:1017. [PubMed: 11870220]
- Shaw M, Compton H, Roos D, Tilney L. *J. Cell Sci* 2000;113:1241. [PubMed: 10704375]
- Chan M, Fong D. *Science* 1990;249:924. [PubMed: 2392684]
- Arrowood M, Mead J, Xie L, You X. *FEMS Microbiol. Lett* 1996;136:245. [PubMed: 8867379]
- Benbow J, Bernberg E, Korda A, Mead J. *Antimicrob. Agents Chemother* 1998;42:339. [PubMed: 9527782]
- Werbovetz K, Sackett D, Delfin D, Bhattacharya G, Salem M, Obrzut T, Rattendi D, Bacchi C. *Mol. Pharmacol* 2003;64:1325. [PubMed: 14645662]
- Mitra A, Sept D. *J. Med. Chem* 2006;49:5226. [PubMed: 16913711]
- Chan M, Triemer RE, Fong D. *Differentiation* 1991;46:15. [PubMed: 2044859]
- Chan M, Tzeng Y, Emge TJ, Ho C-T, Fong D. *Antimicrob. Agents Chemother* 1993;37:1909. [PubMed: 7818612]
- Hugdahl JD, Morejohn LC. *Plant Physiol* 1993;102:725. [PubMed: 12231861]
- Morejohn L, Bureau T, Mole-Bajer J, Bajer A, Fosket D. *Planta* 1987;172:252.
- Bhattacharya G, Salem M, Werbovetz K. *Bioorg. Med. Chem. Lett* 2002;12:2395. [PubMed: 12161141]
- Bhattacharya G, Herman J, Delfin D, Salem M, Barszcz T, Mollet M, Riccio G, Brun R, Werbovetz K. *J. Med. Chem* 2004;47:1823. [PubMed: 15027874]
- George T, Johnsamuel J, Delfin D, Yakovich A, Mukherjee M, Phelps M, Dalton J, Sackett D, Kaiser M, Brun R, Werbovetz K. *Bioorg. Med. Chem* 2006;14:5699. [PubMed: 16675220]
- George T, Endeshaw M, Morgan R, Mahasenan K, Delfin D, Mukherjee M, Yakovich A, Fotie J, Li C, Werbovetz K. *Bioorg. Med. Chem* 2007;15:6071. [PubMed: 17618122]
- Beletskaya I, Cheprakov A. *Coord. Chem. Rev* 2004;248:2337.

34. Maffioli S, Marzorati E, Marazzi A. *Org. Lett* 2005;7:5237. [PubMed: 16268547]
35. Soper, Q. U.S. Patent. 3,442,639. 1969.
36. Hunter, D.; Woods, W.; Stone, J.; LeFevre, C. U.S. Patent. 3,903,078. 1975.
37. Rasheed K, Warkentin J. J. *Org. Chem* 1975;42:1265.

Figure 1.

(A–B) Compound **18b** selectively disrupts microtubules in intracellular *Toxoplasma gondii* but not host vertebrate cells. (A1) Immunofluorescence of DMSO control treated parasite cultures illustrates that vehicle alone does not disrupt either vertebrate host cell (red) or *Toxoplasma* parasite (green) microtubules. Red: host cell microtubules retain a filamentous pattern, which can be seen more clearly in the boxed enlargement. Green: parasite subpellicular microtubules are present in a typical linear array. Blue: DAPI staining of host cell and parasite DNA. (A2) A phase contrast image of the same field; the scale bar represents 5 μ m. (B1) Immunofluorescence of parasite cultures treated for 28 hours with 0.5 μ M **18b** in DMSO show that parasite but not host cells are disrupted. Red: host cell

microtubules retain a filamentous pattern, which can be seen more clearly in the boxed enlargement. Green: parasite subpellicular microtubules are disrupted and free tubulin dimer staining is diffuse rather than organized into linear arrays. Blue: host cell and parasite DNA. (B2) A matched phase contrast image; the scale bar is 5 μm . (C) An MTS viability assay using the *CellTiter* reagent (Promega) illustrates that **6c** and **6e** are toxic to host cells at 30 μM , while 0.5 μM **18b** (~10-fold greater than the antiparasitic IC_{50} value for this compound) does not have significant toxicity. (D–E) Compound **6e** inhibits replication of intracellular *Toxoplasma gondii* but does not disrupt parasite microtubules, indicating that the compound interacts with target(s) other than tubulin. (D1) Immunofluorescence of a control culture: the rosette of eight daughter parasites indicates that the initial intracellular parasite has undergone 3 cycles of replication 28 hours after infection. Red: A parasite-specific surface antigen, P30/SAG1, labels the entire parasite surface. Green: parasite subpellicular microtubules are present in a typical linear array. Blue: host cell and parasite DNA. (D2) A matched phase contrast image; the scale bar is 5 μm . (E1) Immunofluorescence of a culture treated with **6e** showing two single intracellular parasites which have not replicated 28 hours post infection. This culture was set up at the same time as the control culture, and parasite vacuoles should contain 4–16 parasites by 28 hours. Note the intact microtubules in the parasites. Fluorochromes are the same as in the control sample. (E2) A matched phase contrast image; the scale bar is 5 μm . Full experimental methods are given in the supplementary information.

Figure 2.
Activity map for dinitroaniline analogs against *Toxoplasma* microtubules.

Scheme 1.

Reagents and conditions: a) RNH₂, Et₃N, CH₂Cl₂, 0 °C to rt, overnight; b) (i) BH₃-THF (3 equiv), reflux, overnight; (ii) MeOH, reflux, 5h; (iii) Boc₂O (1.5 equiv) in CH₂Cl₂, rt, overnight; (iv) 4 M HCl in 1,4-dioxane (1.3 equiv), CH₂Cl₂, rt, overnight.

Scheme 2.

Reagents and conditions: a) Secondary amine, reflux, or secondary amine hydrochloride, Et_3N , MeOH, reflux, 4 h; b) (i) PCl_5 , CH_2Cl_2 , rt, 3 h; (ii) NH_3 (7 N in MeOH), or amine, Et_3N , THF, 0 °C to rt, 2h.

Scheme 3.

Reagents and conditions: a) (i) $\text{PCl}_5/\text{POCl}_3$, chlorobenzene, reflux, 24; (ii) NH_3 (0.5 M in 1,4-dioxane), 0 °C, 1 hr, rt, 1 h; b) dipropylamine, K_2CO_3 , Cu, dioxane, reflux, 5h; c) 3N NaOH, MeOH, reflux, 2 days; d) (i) $\text{CCl}_3\text{COCCl}_3$, PPh_3 , THF, 0 °C, 1 h; (ii) NH_3 /dioxane, rt, 1 h; e) PdCl_2 , $\text{CH}_3\text{CN}/\text{H}_2\text{O}$, 24 h.

13a, 14a: $\text{R}^1 = \text{NO}_2$, $\text{R}^2 = \text{CF}_3$

13b, 14b: $\text{R}^1 = \text{CF}_3$, $\text{R}^2 = \text{NO}_2$

Scheme 4.

Reagents and conditions: a) Dipropylamine, reflux, overnight.

Scheme 5.

Reagents and conditions: a) Fuming sulfuric acid containing 30–33% SO_3 /fuming 90% nitric acid; b) secondary amine, absolute ethanol, 100 °C, 72 h; c) NH_3 in 1,4-dioxane, 100°C, 40 h.

Table 1

Activity of Target Compounds against *Toxoplasma gondii* In Vitro

Compound	R ₁	R ₂	X	Y	Z	IC ₅₀ (μM) vs. <i>Toxoplasma gondii</i> ^a
6a	Ph	CH ₂ Cl	NO ₂	SO ₂ NH ₂	H	0.85 ± 0.03
6b	Ph	(CH ₂) ₂ Cl	NO ₂	SO ₂ NH ₂	H	2.6 ± 0.1
6c	4-Tolyl	4-Tolyl	NO ₂	SO ₂ NH ₂	H	Non-specific
6d	cHexyl	cHexyl	NO ₂	SO ₂ NH ₂	H	Non-specific
6e	CH ₂ Ph	CH ₂ Ph	NO ₂	SO ₂ NH ₂	H	Non-specific
6f	Ph	Ph	NO ₂	SO ₂ NH ₂	H	Non-specific
6g	Ph	cPr	NO ₂	SO ₂ NH ₂	H	2.1 ± 0.1
6h	CH(CH ₃) ₂	CH(CH ₃) ₂	NO ₂	SO ₂ NH ₂	H	0.35 ± 0.02
6i	CH ₂ CH ₃	CH ₂ CH ₃	NO ₂	SO ₂ NH ₂	H	0.25 ± 0.01
6j	(CH ₂) ₂ CH ₃	(CH ₂) ₂ CH ₃	NO ₂	SO ₂ NH ₂	H	1.1 ± 0.2
6k	CH ₂ CH ₃	CH ₂ CH ₃	NO ₂	SO ₂ NH(CH ₂) ₂ OH	H	26 ± 2
6l	CH ₂ CH ₃	CH ₂ CH ₃	NO ₂	SO ₂ NH(4-phenol)	H	2.6 ± 0.3
6m	CH ₂ CH ₃	CH ₂ CH ₃	NO ₂	SO ₂ NHPh	H	6.7 ± 0.7
6n	CH ₂ CH ₃	CH ₂ CH ₃	NO ₂	SO ₂ N(CH ₃) ₂	H	3.4 ± 0.2
12	CH ₂ CH ₃	CH ₂ CH ₃	CN	SO ₂ NH ₂	H	4.8 ± 0.2
14a	CH ₂ CH ₃	CH ₂ CH ₃	NO ₂	CF ₃	H	0.65 ± 0.06
14b	CH ₂ CH ₃	CH ₂ CH ₃	NO ₂ , CF ₃	NO ₂	H	7.8 ± 1.0
18a	CH ₃	CH ₃	NO ₂	CF ₃	NH ₂	0.070 ± 0.004
18b	CH ₂ CH ₃	CH ₂ CH ₃	NO ₂	CF ₃	NH ₂	0.036 ± 0.002

Compound	R ₁	R ₂	X	Y	Z	IC ₅₀ (μM) vs. <i>Toxoplasma gondii</i> ^a
18c	(CH ₂) ₂ CH ₃	(CH ₂) ₂ CH ₃	NO ₂	CF ₃	NH ₂	0.51 ± 0.02

^a Mean ± standard deviation of three independent measurements, experimental methods are given in the supplementary information.